Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Blood blood.2024025454.

https://doi.org/10.1182/blood.2024025454

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel

Blood (2024) 143 (9): 822–832.

https://doi.org/10.1182/blood.2023022348

Published: 2024

Includes: Supplemental data

Journal Articles

Baseline CD4 T Cells Are Associated with Improved Response to CD20-CD3 Bispecifics in Lymphoma

Christopher R. Bolen, Sumedha Roy, Ling-Yuh Huw, Katerina Hatzi, Elicia Penuel

Blood (2023) 142 (Supplement 1): 3005.

https://doi.org/10.1182/blood-2023-186771

Published: 2023

Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster

Blood (2023) 142 (Supplement 1): 1752.

https://doi.org/10.1182/blood-2023-190201

Published: 2023

Journal Articles

Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma

Victor Maximov, Christopher R. Bolen, Andrew G. Polson, Elicia Penuel, Elisabeth A. Lasater

Blood (2023) 142 (Supplement 1): 2808.

https://doi.org/10.1182/blood-2023-187696

Published: 2023

Journal Articles

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel

Blood (2023) 142 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2023-181723

Published: 2023

Journal Articles

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 603.

https://doi.org/10.1182/blood-2023-173692

Published: 2023

Journal Articles

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Ling-Yuh Huw, Feifei Li, Anton Belousov, Hemanth Ramesha, Christopher R. Bolen, Michael C. Wei, Shen Yin, David C. Turner, Elicia Penuel

Blood (2022) 140 (Supplement 1): 6448–6449.

https://doi.org/10.1182/blood-2022-157934

Published: 2022

Journal Articles

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Huang Huang, Juliana Min, Elicia Penuel, L. Elizabeth Budde

Blood (2022) 140 (Supplement 1): 1467–1470.

https://doi.org/10.1182/blood-2022-157691

Published: 2022

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Jason Westin, Adam J. Olszewski, Laura Maria Fogliatto, Won-Seog Kim, Ho-Jin Shin, Hao Wu, Shen Yin, Song Pham, Elicia Penuel, Jing Jing, Michael C. Wei, Elizabeth L. Budde

Blood (2022) 140 (Supplement 1): 3771–3772.

https://doi.org/10.1182/blood-2022-157710

Published: 2022

Journal Articles

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2021-147937

Published: 2021

Journal Articles

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Blood (2021) 138 (Supplement 1): 127.

https://doi.org/10.1182/blood-2021-145872

Published: 2021

Journal Articles

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Elisabeth A Lasater, PhD, An D Do, Luciana Burton, Yijin Li, Erin Williams, Jason Oeh, Luciana Molinero, Elicia Penuel, Deepak Sampath, Monique Dail, Marcia Belvin, Teiko Sumiyoshi, Elizabeth A Punnoose, Jeffrey Venstrom, Aparna Raval

Blood (2018) 132 (Supplement 1): 1118.

https://doi.org/10.1182/blood-2018-99-116405

Published: 2018

Journal Articles

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Laurie H Sehn, MDMPH, Alex F. Herrera, MD, Matthew J Matasar, Manali Kamdar, Sarit Assouline, Mark Hertzberg, Tae Min Kim, Won-Seog Kim, Andrew McMillan, Muhit Özcan, Jamie M Hirata, Elicia Penuel, Ji Cheng, Grace Ku, Christopher R Flowers, MDMS

Blood (2018) 132 (Supplement 1): 1683.

https://doi.org/10.1182/blood-2018-99-118551

Published: 2018

Journal Articles

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

Laurie H. Sehn, MDMPH, Alex F. Herrera, MD, Matthew J. Matasar, MD, Manali Kamdar, Andrew K. McMillan, FRCP, Tae Min Kim, Won Seog Kim, MD, Ph. D., Mark Hertzberg, MBBS, PhD, Muhit Ozcan, MD, Elicia Penuel, Ji Cheng, Jamie M. Hirata, Grace Ku, Christopher Flowers, MD

Blood (2017) 130 (Supplement 1): 2821.

https://doi.org/10.1182/blood.V130.Suppl_1.2821.2821

Published: 2017

Journal Articles

A Phase I Study of the Anti-CD79b THIOMAB TM -Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Alex F. Herrera, MD, Manish R Patel, MD, John M. Burke, MD, Ranjana H. Advani, MD, Bruce D. Cheson, MD, Jeffrey P. Sharman, MD, Elicia Penuel, Andrew G. Polson, PhD, Ning Leng, PhD, Chunze Li, PhD, Eva Schuth, PhD, Anjali Vaze, PhD, Divya Samineni, PhD, Rebecca Elstrom, MDMA, Catherine S Diefenbach

Blood (2017) 130 (Supplement 1): 4129.

https://doi.org/10.1182/blood.V130.Suppl_1.4129.4129

Published: 2017

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brian G. Till, MD, Steven I. Park, MD, Leslie L. Popplewell, MD, Andre Goy, MD, Elicia Penuel, PhD, Jeffrey M Venstrom, MD, Bo Liu, Guenter Fingerle-Rowson, MD PhD, John Byon, MD PhD, Paul Woodard, MD, M. Lia Palomba, MD

Blood (2015) 126 (23): 5104.

https://doi.org/10.1182/blood.V126.23.5104.5104

Published: 2015

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4029.

https://doi.org/10.1182/blood.V120.21.4029.4029

Published: 2012

NARROW

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Baseline CD4 T Cells Are Associated with Improved Response to CD20-CD3 Bispecifics in Lymphoma

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study

Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study

Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents

Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study

Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study

A Phase I Study of the Anti-CD79b THIOMAB TM -Drug Conjugate DCDS0780A in Patients (pts) with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only